Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Idexx Laboratories (IDXX)

Idexx Laboratories (IDXX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 23,731,126
  • Shares Outstanding, K 85,330
  • Annual Sales, $ 2,407 M
  • Annual Income, $ 427,720 K
  • 60-Month Beta 0.76
  • Price/Sales 9.98
  • Price/Cash Flow 46.81
  • Price/Book 135.77

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate 1.23
  • Number of Estimates 4
  • High Estimate 1.28
  • Low Estimate 1.17
  • Prior Year 1.17
  • Growth Rate Est. (year over year) +5.13%

Price Performance

See More
Period Period Low Period High Performance
1-Month
269.49 +3.20%
on 01/31/20
296.25 -6.12%
on 02/19/20
-6.73 (-2.36%)
since 01/21/20
3-Month
246.74 +12.71%
on 12/03/19
296.25 -6.12%
on 02/19/20
+17.42 (+6.68%)
since 11/21/19
52-Week
198.74 +39.93%
on 03/08/19
296.25 -6.12%
on 02/19/20
+72.12 (+35.01%)
since 02/21/19

Most Recent Stories

More News
Fresenius Medical (FMS) Q4 Earnings Beat Estimates, Up Y/Y

Fresenius Medical's (FMS) fourth-quarter earnings benefit from strong segmental performance and solid 2020 EPS outlook.

SYK : 224.30 (-0.08%)
ARAY : 3.32 (-1.48%)
FMS : 41.01 (-2.40%)
IDXX : 278.11 (-1.19%)
Integer Holdings (ITGR) Q4 Earnings & Revenues Top Estimates

Integer Holdings' (ITGR) fourth-quarter earnings benefit from higher revenues and strong segmental performance.

SYK : 224.30 (-0.08%)
ARAY : 3.32 (-1.48%)
IDXX : 278.11 (-1.19%)
ITGR : 97.85 (-1.09%)
Masimo (MASI) Q4 Earnings Beat Estimates, View Impressive

Masimo (MASI) sees expansion in gross and operating margin in Q4.

SYK : 224.30 (-0.08%)
ARAY : 3.32 (-1.48%)
MASI : 178.37 (-1.89%)
IDXX : 278.11 (-1.19%)
Idexx Labs Rises 2.44% on Heavy Volume: Watch For Potential Pullback

Idexx Labs (NASDAQ:IDXX) traded in a range yesterday that spanned from a low of $288.00 to a high of $289.74. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $289.01...

IDXX : 278.11 (-1.19%)
Amedisys (AMED) Q4 Earnings Beat Estimates, Revenues Miss

Amedisys' (AMED) fourth-quarter earnings benefit from solid year-over-year growth in Medicare and non-Medicare revenues within Home Health.

SYK : 224.30 (-0.08%)
AMED : 194.03 (-0.05%)
ARAY : 3.32 (-1.48%)
IDXX : 278.11 (-1.19%)
Ecolab (ECL) Earnings and Revenues Miss Estimates in Q4

Strength in the Global Industrial arm drives Ecolab's (ECL) Q4 results.

ECL : 207.50 (+0.58%)
SYK : 224.30 (-0.08%)
ARAY : 3.32 (-1.48%)
IDXX : 278.11 (-1.19%)
IDEXX Laboratories to Present at Two Upcoming Institutional Investor Conferences

IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, will participate in two upcoming conferences:

IDXX : 278.11 (-1.19%)
Change Healthcare (CHNG) Q3 Earnings Top Estimates, Down Y/Y

Change Healthcare's (CHNG) third-quarter fiscal earnings benefit from solid performance across the segments - Software and Analytics and Network Solutions. However, decline in revenues remains a woe.

SYK : 224.30 (-0.08%)
ARAY : 3.32 (-1.48%)
IDXX : 278.11 (-1.19%)
CHNG : 16.01 (+0.95%)
DexCom (DXCM) Q4 Earnings and Revenues Surpass Estimates

DexCom's (DXCM) fourth-quarter earnings benefit from higher revenues and solid performing Sensor and Transmitter segments.

SYK : 224.30 (-0.08%)
ARAY : 3.32 (-1.48%)
DXCM : 291.25 (-3.72%)
IDXX : 278.11 (-1.19%)
AMN Healthcare (AMN) Q4 Earnings and Revenues Top Estimates

AMN Healthcare's (AMN) Q4 results gain from core Nurse and Allied Solutions units.

SYK : 224.30 (-0.08%)
ARAY : 3.32 (-1.48%)
AMN : 74.15 (-0.24%)
IDXX : 278.11 (-1.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Trade IDXX with:

Business Summary

IDEXX Laboratories, Inc. is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. IDEXX products enhance the ability of veterinarians to provide advanced medical care, improve staff...

See More

Key Turning Points

2nd Resistance Point 283.50
1st Resistance Point 280.80
Last Price 278.11
1st Support Level 276.10
2nd Support Level 274.10

See More

52-Week High 296.25
Last Price 278.11
Fibonacci 61.8% 259.00
Fibonacci 50% 247.50
Fibonacci 38.2% 235.99
52-Week Low 198.74

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar